Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme in the UK

被引：0
|
作者：
Uyl-de Groot, CA
Lamers, LM
Al, M
van den Bent, M
Gorlia, T
Crott, R
Mason, W
Stupp, R
机构：
[1] Univ Med Ctr Rotterdam, Erasmus MC, Rotterdam, Netherlands
[2] EORTC, Brussels, Belgium
[3] Ctr Fed Expertise Soins Sante, Brussels, Belgium
[4] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[5] Univ Lausanne Hosp, Lausanne, Switzerland
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)67204-X
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A21 / A21
页数：1
相关论文
共 50 条
  • [31] Using temozolomide in newly diagnosed glioblastoma multiforme - a single-centre experience
    Ziolkowska, Ewa
    Wisniewski, Tomasz
    Zarzycka, Malgorzata
    Windorbska, Wieslawa
    Lebioda, Andrzej
    Makarewicz, Roman
    [J]. WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2010, 14 (04): : 259 - 264
  • [32] THE COST-EFFECTIVENESS OF TUMOR-TREATING FIELDS IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
    Armoiry, X.
    Auguste, P.
    Dussart, C.
    Guyotat, J.
    Connock, M.
    [J]. NEURO-ONCOLOGY, 2019, 21 : 68 - 68
  • [33] BEVACIZUMAB IN COMBINATION WITH TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE, AND IRINOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME
    Vredenburgh, James
    Desjardins, Annick
    Reardon, David
    Rich, Jeremy
    Kirkpatrick, John
    Gururangan, Sridharan
    Bailey, Leighann
    Friedman, Allan
    Bigner, Darell
    Friedman, Henry
    [J]. NEURO-ONCOLOGY, 2008, 10 (05) : 836 - 837
  • [34] Cost-effectiveness analysis of the addition of bevacizumab to temozolomide therapy for the treatment of unresected glioblastoma
    Chen, Zhaoyan
    Zhan, Mei
    Tian, Fangyuan
    Xu, Ting
    [J]. ONCOLOGY LETTERS, 2020, 19 (01) : 424 - 430
  • [35] The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma
    Bernard-Arnoux, F.
    Lamure, M.
    Ducray, F.
    Aulagner, G.
    Honnorat, J.
    Armoiry, X.
    [J]. NEURO-ONCOLOGY, 2016, 18 (08) : 1129 - 1136
  • [36] Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme
    David M. Peereboom
    Dale R. Shepard
    Manmeet S. Ahluwalia
    Cathy J. Brewer
    Neeraj Agarwal
    Glen H. J. Stevens
    John H. Suh
    Steven A. Toms
    Michael A. Vogelbaum
    Robert J. Weil
    Paul Elson
    Gene H. Barnett
    [J]. Journal of Neuro-Oncology, 2010, 98 : 93 - 99
  • [37] Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme
    Chang, SM
    Lamborn, KR
    Malec, M
    Larson, D
    Wara, W
    Sneed, P
    Rabbitt, J
    Page, M
    Nicholas, MK
    Prados, MD
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (02): : 353 - 357
  • [38] Phase II Trial of Hypofractionated IMRT With Temozolomide for Patients With Newly Diagnosed Glioblastoma Multiforme
    Reddy, Krishna
    Damek, Denise
    Gaspar, Laurie E.
    Ney, Douglas
    Waziri, Allen
    Lillehei, Kevin
    Stuhr, Kelly
    Kavanagh, Brian D.
    Chen, Changhu
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : 655 - 660
  • [39] Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme
    Peereboom, David M.
    Shepard, Dale R.
    Ahluwalia, Manmeet S.
    Brewer, Cathy J.
    Agarwal, Neeraj
    Stevens, Glen H. J.
    Suh, John H.
    Toms, Steven A.
    Vogelbaum, Michael A.
    Weil, Robert J.
    Elson, Paul
    Barnett, Gene H.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2010, 98 (01) : 93 - 99
  • [40] Temozolomide with or without Radiotherapy in Patients with Newly Diagnosed Glioblastoma Multiforme: A Meta-Analysis
    Feng, Enshan
    Sui, Changbai
    Wang, Tongxin
    Sun, Gaoling
    [J]. EUROPEAN NEUROLOGY, 2017, 77 (3-4) : 201 - 210
12345